FDA Approves Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn for ALL and LBL

The FDA granted approval to asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze™, Jazz Pharmaceuticals, Inc.) as part of a multi-agent chemotherapeutic regimen for patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) who have developed hypersensitivity to E. coli-derived asparaginase. Asparaginase erwinia chrysanthemi (recombinant)-rywn is an alternative to the only other FDA-approved drug for patients with this allergic reaction, which has been in short sup...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.